In the latest controversy, the Ayurveda and Unani Licensing Authority in Dehradun has ordered Patanjali's Divya Pharmacy to stop production of these five drugs that claimed treatment for blood pressure, diabetes, goitre, glaucoma, and high cholesterol.
The Ayurveda and Unani Licensing Authority in Uttarakhand's Dehradun has asked Patanjali's Divya Pharmacy to stop producing five drugs — Madhugiri, Eyegrit, Thyrogrit, BPgrit, and Lipidom. Apart from the drug production ban, Patanjali has been instructed to stop misleading advertisements immediately. The authority has asked Patanjali to come up with future ads only after approval from the authority.
Recommended ArticlesView All
Decoding multi-year health insurance policy — What is it and what are key benefits?
IST3 Min(s) Read
View | Pakistan Election: Will Imran Khan's changed tack from long march to resignations to snap poll work?
IST5 Min(s) Read
View | G20 Presidency: India can shape global Web3 narrative
IST6 Min(s) Read
Patanjali's Divya Pharmacy has said that production could restart only after the authority has approved the revised indications. The order comes after the company was accused of promoting these drugs to treat blood pressure, diabetes, goitre, glaucoma, and high cholesterol.
The Uttarakhand licensing authority found "repeated contravention of provisions under Drugs & Magic Remedies (objectionable advertisement) Act 1954 & Drugs and Cosmetics Act 1940 & Rules 1945" by Patanjali's Divya Pharmacy.
A letter asking Patanjali's Divya Pharmacy to halt the manufacturing was sent on Wednesday, November 9.
CNBCTV18 is awaiting comments from Patanjali.
Also Read:Indian Yoga Guru accuses Bollywood stars, Salman Khan of consuming drugs in viral video: Watch here
First Published: IST